PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, 60 persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

US-

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Complete if Known	
Application Number	09/517,898	
Filing Date	March 3, 2000	
First Named Inventor	Vogels et al.	
Group Art Unit	1632	
Examiner Name	Q. Li	
Attorney Docket Number	2578-3982.2US	

		Document Number	U.S. PATENT DO	Name of Patentee or Applicant of		
	Cite No.1 Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
XA		US-5,631,236	05-1997	Woo et al.		
A		US- 5,770,442	06-1998	Wickham et al.		
	1	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
-		US-			<u> </u>	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Cite Initials No.	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	1 tppiiotiii 01 01100	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
0		97/00326	01/03/1997	Introgene B.V.		
·	 					
				· · · · · · · · · · · · · · · · · · ·		
	•					

Examiner Signature	& Hart.	Date Considered	6/20/03	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional) . <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Aroun 1994, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

(use us many sneets us necessary)

	Complete if Known	
Application Number	09/517,898	
Filing Date	March 3, 2000	
First Named Inventor	Vogels et al.	
Group Art Unit	1632	
Examiner Name	Q. Li	
Attorney Docket Number	2578-3982 2US	

Examiner Initials/*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т 2
		Crystal et al., Transfer of Gene to Human: Early Lessons and Obstacles to Success, 1995, Science, Vol. 270, pp. 404-10.	
		Eck et al., Gene-Based Therapy, 1996 Goodman & Gilman's, pp. 77-101.	
		Gall et al., Journal of Virology, 1996, pp. 2116-23, Vol. 70.	
		Guzman et al., PNAS, 1994, pp. 10732-36, Vol. 91.	
		Kaye et al., A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, September 1990, Proc. Natl. Acad. Sci., pp. 6922-26, Vol. 87.	
		Lusky et al., Journal of Virology, 1998, pp. 2022-32, Vol. 72.	
- O		Rudinger et al., Characteristics of the armino acids as components of a peptide hormone sequence, 1976, Peptide Hormones, pp. 1-7.	
		Su, et al., A Genetically Modified Adenoviral Vector Exhibits Enhanced Gene Transfer of Human Smooth Muscle Cells, Journal of Vascular Research 2001, pp. 471-78, Vol. 38.	
7		Wickham et al., Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Protein, Nov. 1997, Journal of Virology, pp. 8221-29, Vol. 71, No. 11.	
1		Wilson et al., Adenovirus Vectors in the Development of Gene Therapy, 1999, Friedman, T ed. CSHL Press, Cold Spring Harbor, New York.	

Examiner Signature Date Considered 6/26/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.